Insight Molecular Diagnostics Inc. IMDX
Set alert
2.83 USD -0.03 -1.05%
As of Nov 3, 2:21 PM ET
2.74 Day range 3.12
2.42 52-week range 8.51
- YTD
- -62.27%
- 1 year
- -53.76%
- Open
- 3.12
- Prev close
- 2.86
- Mkt cap
- 92.61M
- Vol
- 62.15K
- Avg vol
- 245.65K
- EPS
- -1.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.74
- High
- 3.12
1m chart
Built from the cached one-day intraday bars.
Signals (8)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Nov 3, 11:32 AM | 2 hours ago |
| MACD: Sell Signal | Nov 3, 11:23 AM | 3 hours ago |
| SMA: Bearish | Nov 3, 11:22 AM | 3 hours ago |
| RSI: Overbought | Nov 3, 11:14 AM | 3 hours ago |
| MACD: Buy Signal | Nov 3, 11:00 AM | 3 hours ago |
| MACD: Sell Signal | Nov 3, 10:47 AM | 3 hours ago |
| RSI: Oversold | Nov 3, 10:47 AM | 3 hours ago |
| SMA: Bullish | Nov 3, 10:02 AM | 4 hours ago |
Financials — quick view
IMDX Revenue — quarterly 239.00K
IMDX Net income — quarterly -11.26M
IMDX EPS — quarterly -0.31
News
- Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Analysis
- iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
- iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale
- iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
- LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8
- Transcript: Insight Molecular Q2 2026 Earnings Conference Call
- Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
- Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
- Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
- Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on IMDX — it syncs with the Stock Master app.